This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters.
Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
本发明涉及新型 1,4-二氮双环[3.2.2]壬基噁二唑基衍
生物及其在药物组合物生产中的应用。本发明的化合物是
烟碱乙酰胆碱受体的
胆碱能
配体,也是单胺受体和转运体的调节剂。
由于其药理特性,本发明化合物可用于治疗各种疾病或失调,如与中枢神经系统(CNS)、周围神经系统(
PNS)的
胆碱能系统有关的疾病或失调、与平滑肌收缩有关的疾病或失调、内分泌疾病或失调、与神经变性有关的疾病或失调、与炎症有关的疾病或失调、疼痛以及终止滥用
化学物质引起的戒断症状。